Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Investor Presentation (August 2025)
27 slides from Sanara Medtech's investor presentation, August 2025
Slide 1: Sanara MedTech Investor Presentation
Sanara MedTech Investor Presentation August 2025
Slide 2: Disclaimers
Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the “Company,” “Sanara,” “we,” “our” or “us”). All statements othe
Slide 3: Sanara MedTech Key Attributes
Sanara MedTech Key Attributes Commercial Scale, Strong Growth & Operating Leverage Sanara MedTech at a Glance • Demonstrated track record of strong, sustainable revenue growth fueled by our commercial team and lead product, Ticker (Nasdaq) SMTI CellerateRX ® Surgical Powder Market Cap $284.2M(1) • S
Slide 4: Sanara MedTech: Who We Are
Sanara MedTech: Who We Are Mission Statement & Strategy Sanara empowers healthcare professionals to maximize patient outcomes through innovative MedTech products that deliver cost savings Sanara MedTech provides advanced tissue repair solutions for surgical patients and individuals with skin and wou
Slide 5: History of Growth
History of Growth Demonstrated Track Record of Innovation, Expansion and Net Revenue Growth 2024 • $55 million debt facility to drive 2018-2024 future growth • Signed with major Net Revenue CAGR: 57% 2022 national GPO • 2 new distribution • Scendia deals Biologics, LLC 2020 acquisition 2019 • InfuSy
Slide 6: Sanara MedTech Surgical Segment
Sanara MedTech Surgical Segment
Slide 7: © 2025 Sanara MedTech Inc. All Rights Reserved.
7 © 2025 Sanara MedTech Inc. All Rights Reserved.
Slide 8: Sanara Surgical Segment
Sanara Surgical Segment Portfolio Built to Complement Surgical Outcomes & Reduce Post-Op Cost Empowering surgeons to deliver improved patient outcomes by offering high value, niche products Segment Sales & Distribution Overview (1) Key Differentiators Driving Future Growth $97.2M TTM Net 1. Highly a
Slide 9: Sanara Surgical Segment: Recent Peer-Reviewed Research Studies
Sanara Surgical Segment Recent Peer-Reviewed Research Studies Multispecialty Spine Journal of Surgery JSM Neurosurgery and Spine Activated Collagen Powder Significantly The Use of Sterile Bovine Type 1 Reduces Surgical Site Infections in Hydrolyzed Collagen to Support Surgical Patients Undergoing El
Slide 10: Sanara Surgical Segment: Growth Opportunities
Sanara Surgical Segment Growth Opportunities Expand in Existing Specialties Expand Hospital Footprint • Ortho & Spine focus with CellerateRX® • Enter contracted but currently unsold • Drive deeper adoption in 1,300+ hospitals hospitals • Leverage national GPO contract (1,000+ • Increased sales rep a
Slide 11: Sanara MedTech Tissue Health Plus Segment
Sanara MedTech Tissue Health Plus Segment
Slide 12: The Chronic Wound Care Challenge
The Chronic Wound Care Challenge $100B+* annual expenditure that is under-managed with subpar outcomes Highly Inefficient Flawed Care Cumbersome Spend Model Administration o 69% in high-cost o Fragmented care across o Highest audited spend settings, namely settings area hospitals* o Reactive, non- o
Slide 13: Tissue Health Plus Breakthrough Approach
Tissue Health Plus Breakthrough Approach Patient & Value Centric Programs Planned to Shift Care to the Home Proactively engage patients and orchestrate wound care journeys Transform care and optimize economics through technology Develop Optimal Care Plans & Standardize and Transform Care at Optimize
Slide 14: Tissue Health Plus Market Opportunity
Tissue Health Plus Market Opportunity Several Promising Market Segments; 1st Focus is Medicare Advantage $58-84B TAM across distinct market segments Wound Multiple tailwinds Segment TAM* Business Model Launch Patients* accelerating adoption Aging population increasing wound Medicare incidence by 6-8
Slide 15: 2Q 2025 and 1H 2025 Financial Highlights
Sanara MedTech 2Q 2025 and 1H 2025 Financial Highlights
Slide 16: 2Q 2025 Financial Highlights
2Q 2025 Financial Highlights (1) Net Revenue ($M) Segment Adjusted EBITDA ($M) $6.0 $5.0 $25.8 $4.0 $30.0 $20.2 $3.0 $25.0 $2.0 $4.7 $20.0 $1.0 $1.4 $- $15.0 $(0.8) $10.0 $(1.0) $(2.1) $(2.0) $5.0 $(3.0) $- 2Q24 2Q25 2Q24 2Q25 Sanara Surgical THP 28% year-over-year net revenue growth Consolidated 2Q
Slide 17: 1H 2025 Highlights
1H 2025 Highlights (1) Net Revenue ($M) Segment Adjusted EBITDA ($M) $8.0 $49.3 $6.0 $4.0 $50.0 $38.7 $7.4 $2.0 $45.0 $2.5 $40.0 $- $35.0 $(1.6) $30.0 $(2.0) $(4.1) $(4.0) $25.0 $20.0 $(6.0) $15.0 $10.0 1H2024 1H2025 $5.0 Sanara Surgical THP $- 1H2024 1H2025 Consolidated 1H25 Adjusted EBITDA of $3.3
Slide 18: Appendix
Appendix Sanara MedTech Evidence Based Healing
Slide 19: Q2 2025 and 1H25 Segment Reporting
Q2 2025 and 1H25 Segment Reporting Segment Reporting Overview • Break out of Sanara Surgical and Tissue Health Plus demonstrates our strategic rationale of the acute/post acute comprehensive strategy investments Three Months Ended June 30, 2025 ($M) Three Months Ended June 30, 2024 ($M) Surgical THP
Slide 20: Q2 2025 Financial Summary
Q2 2025 Financial Summary (unaudited) Net Revenue • Net revenue for the second quarter of 2025 was $25.8 million, compared to $20.2 million for the second quarter of 2024, an increase of $5.7 million, or 28%, year-over-year. • The increase in net revenue was primarily driven by an increase of $5.0 m
Slide 21: Q2 2025 Financial Summary (Continued)
Q2 2025 Financial Summary (Continued) Net Income (Loss) • Net loss for the second quarter of 2025 was $2.0 million, compared to a net loss of $3.5 million for the second quarter of 2024. • The Company’s Sanara Surgical segment generated a net income of $0.5 million for the second quarter of 2025, co
Slide 22: Sources
Sources Slides 3 & 4 • Understanding the costs associated with surgical care delivery in the Medicare population - PMC • Hospital and Payer Costs Associated With Surgical Complications - PubMed Slides 12 and 14 • THP Analysis + Carter MJ, DaVanzo J, Haught R, et al. Chronic wound prevalence and the
Slide 23: Non-GAAP Financial Measures
Non-GAAP Financial Measures Use of Non-GAAP Financial Measures To supplement the Company’s financial information presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we present certain non-GAAP financial measures in this presentation, including Adjuste
Slide 24: Reconciliation of GAAP to Non-GAAP Financial Measures – Q2 2025
Reconciliation of GAAP to Non-GAAP Financial Measures – Q2 2025 Three Months Ended June 30, 2025 2024 Sanara Sanara Surgical THP (3) Total Surgical THP Total Net Income (Loss) $ 507,280 $(2,525,678) $ (2,018,398) $ (2,214,313) $(1,314,889) $(3,529,202) Adjustments: Interest expense 1,791,568 - 1,791
Slide 25: Reconciliation of GAAP to Non-GAAP Financial Measures – 1H2025
Reconciliation of GAAP to Non-GAAP Financial Measures – 1H2025 Six Months Ended June 30, 2025 2024 Sanara Sanara Surgical THP (3) Total Surgical THP Total Net Loss $ (107,825) $ (5,437,956) $ (5,545,781) $ (2,691,798) $(2,636,447) $(5,328,245) Adjustments: Interest expense 3,108,660 - 3,108,660 911,
Slide 26: Reconciliation of GAAP to Non-GAAP Financial Measures – TTM Q2-2025
Reconciliation of GAAP to Non-GAAP Financial Measures – TTM Q2-2025 Trailing Twelve Months Ended June 30, 2025 Sanara Surgical THP (3) Total Net (Income) Loss $ 646,391 $ (10,775,824) $ (10,129,433) Adjustments: Interest expense 5,325,373 - 5,325,373 Depreciation and amortization 2,759,016 2,191,922
Slide 27: Thank You
Thank You 4 Sanara MedTech Evidence Based Healing